ABAM Transitional Maintenance of Certification

Transitional Maintenance of Certification (tMOC) is a fundamental part of addiction medicine certification for current ABAM Diplomates. For more information or questions about the ABAM tMOC program, visit ABAM's website.

All of the courses below have been approved by the American Board of Addiction Medicine for tMOC.

ABAM tMOC Approved Courses

  • The ASAM Treatment of Opioid Use Disorder Course

    Product not yet rated Contains 9 Component(s), Includes Credits

    This 8-hour online course provides required education to qualify for the waiver to prescribe buprenorphine in an office-based setting and covers essential information for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD).

    image

    The ASAM Treatment of Opioid Use Disorder Course


    NEW 8-Hour Online Course for Physicians*

    The ASAM Treatment of Opioid Use Disorder Course provides eight hours of required education to qualify for the waiver to prescribe buprenorphine in an office-based setting and covers essential information for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD). The course covers the latest information on medications and treatments for OUD. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This course is fully online and can be completed at your own pace. The flow of this online course uses a mix of didactic materials, case studies, learning activities, and assessments.

    Begin the course by reviewing the Getting Started page that contains information about the structure and sequence of the course. From there, you can review the course introduction, faculty information, content modules, and different sections of the course to get acquainted with course navigation.

    *NPs, PAs, CNMs, CRNAs, and other CNSs are required to complete no less than 24 hours of training. ASAM offers 24 hour packages for free. Click here for more information.

    Note: Resident & Fellow ASAM Members (in training) receive complimentary access to The ASAM Treatment of Opioid Use Disorder Course. Click here to become a member. Please note membership approval requires up to two business days.


    Quick Links 


    Target Audience

    • Physicians who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
    • Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.

    Getting Started


    Structure of the Course

    It's important to familiarize yourself with the overall structure and elements of the environment in which you will be learning. This online course is fully online and self-paced. The course content, learning activities, and assessments in the course should be completed asynchronously—you will log into the course site and complete them at your own pace. The course will take approximately 8 hours to complete.

    All content modules are available under the Course Content tab in the course navigation.

    Module Structure

    image

    Overview

    This section serves as an introduction to the module.

     
     
    image

    Learning Objectives

    The learning objectives for the module are listed here.

     
     
    image

    Module Introduction

    The introduction provides an overview of the upcoming content.

     
     
    image

    Module Content

    This section contains content and learning materials you need to read or view.

     
     
    image

    Practice/Reflection Exercise

    This section contains practice exercises to help you work toward mastery of the concepts.

     
     
    image

    Assessment

    Each module contains a short assessment to test your mastery of the learning objectives.

    Course Introduction


    image

    The ASAM Treatment of Opioid Use Disorder Course 8-Hour Online

    The ASAM Treatment of Opioid Use Disorder Course provides the required education essential for providers to identify, assess, diagnose, and manage patients with opioid use disorder (OUD). The course covers all medications and treatments for OUD. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 


    image

    Learning Objectives

    Upon completion, you will be able to:

    • Identify, assess, and diagnose patients with opioid use disorder while considering severity, chronicity, individual characteristics, and psychiatric and medical comorbidities.
    • Develop an individualized, patient-centered treatment plan, including negotiating treatment goals by evaluating appropriate medication- and psychosocial-based treatment options.
    • Monitor progress and modify treatment plans based on patient needs and progress toward treatment goals.
    • Implement best practices for office systems, including team-based care, to support treatment with medications for opioid use disorder.
    • Examine misconceptions, stigma, and complexities (bioethical, social, clinical, public health) associated with opioid use disorder and the use of medications to treat opioid use disorder.

    Faculty


    image

    Daniel P. Alford, MD, MPH, FACP, DFASAM

    image

    Dr. Daniel Alford is a Professor of Medicine and Associate Dean of Continuing Medical Education at Boston University School of Medicine (BUSM). He is on staff in the Section of General Internal Medicine and Director of the Clinical Addiction Research and Education (CARE) Unit at Boston Medical Center. He is the Medical Director of the CDC-funded Boston Sustainable Models for unhealthy Alcohol use ReducTion (B SMART) and the HRSA funded SBIRT And FASD Education, Support and Treatment (SAFEST) Choice programs. 

    Dr. Daniel Alford has no relevant financial disclosures.


    image

    Debra Newman, PA-C, MPAS, MPH

    image

    Debra Newman currently serves as a treatment provider for First Judicial District Court, Adult Drug Court for Santa Fe and Rio Arriba Counties, New Mexico. She is also working part-time as a contract provider in Chemical Dependency for Kaiser Permanente in Denver, Colorado. Debra has worked in residential treatment as well as out-patient adult psychiatry and addiction medicine. She is currently working with the PA Foundation and NIDA on a grant examining the role of PAs in drug courts. 

    Debra Newman has no relevant financial disclosures.


    image

    Yngvild K. Olsen, MD, MPH, DFASAM

    image

    Dr. Yngvild Olsen graduated from Harvard Medical School in 1997, from the residency training program in internal medicine at Boston Medical Center in 2000, and from the Fellowship in General Internal Medicine at the Johns Hopkins School of Medicine in 2001. Dr. Olsen also serves as the Medical Director of the Institutes for Behavior Resources Inc/REACH Health Services in Baltimore City. Dr. Olsen currently serves as Vice President of the American Society of Addiction Medicine and is a member of the Public Policy Committee. She is the Immediate Past President of the Maryland Society of Addiction Medicine, Immediate Past President of the Maryland Association for the Treatment of Opioid Dependence, and a Board member of the National Council on Alcoholism and Drug Dependence-MD (NCADD-MD). 

    Yngvild K. Olsen has no relevant financial disclosures.


    image

    Edwin Salsitz, MD, DFASAM

    image

    Dr. Edwin Salsitz has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM) and the Board of Internal Medicine and Pulmonary Disease. 

    Dr. Edwin Salsitz has no relevant financial disclosures.


    image

    Kristin E. Smith, DNP, FNP-C

    image

    Kristin Smith graduated from St. John Fisher’s FNP/DNP program in May 2013. She is a staff clinician and the Program Director of a Nurse Practitioner (NP) Residency Program at Highland Family Medicine, where she provides Medication Assisted Treatment (MATx) in both dedicated suboxone clinics as well as integrated primary care settings. Dr. Smith is also a certified American Academy of HIV Medicine Specialist with experience providing HIV care and Pre/Post-Exposure prophylaxis. Prior to transitioning to her current role, she served as the Clinical Director of an Opioid Overdose Prevention Program, where she became passionate about harm reduction while providing community training on Naloxone, teaching safe injection practices, and providing needle exchange services in collaboration with a team of individuals through Trillium Health.

    Kristin Smith has no relevant financial disclosures.


    image

    Bernard Stuetz PA-C, MA

    image

    Bernard Stuetz is the Past President of the Society of Physician Assistants in Addiction Medicine and currently acting as Chief Delegate to the American Academy of PAs (AAPA) House of Delegates (HOD). He is also the Director for Federal Affairs. He has been a delegate to the AAPA HOD for 31 years. He was a member of the AAPA Recertification Committee in 2012, during which he recommended changes to the ten-year cycle requirements. As a delegate in the AAPA HOD, he was the lead advocate to change the re-certification cycle from six to ten years. He was the first PA to work in the White House on Health Care Policy from 1993 to 1995. Having practiced Addiction Medicine for 25 years, Mr. Stuetz currently works in an OTP and Buprenorphine practice.

    Bernard Stuetz has no relevant financial disclosures.


    image

    Matt Tierney, APRN

    image

    Matt Tierney is a Nurse Practitioner and a Clinical Professor at the UCSF School of Nursing. He also serves as Clinical Director of Substance Use Treatment and Education for the Office of Population Health at UCSF Health. The focus of his career has been on improving essential addiction treatment delivery locally, regionally, and nationally. He is a Fellow of the American Academy of Nursing, where he serves on the Expert Panel on Psychiatric-Mental Health and Substance Use. Matt is also President-Elect of the American Psychiatric Nurses Association and represents APNA as a sponsoring member of the National Academies of Science Engineering and Medicine's Forum of Mental Health and Substance Use Disorders. He is an ASAM member who has been teaching waiver training courses since 2008. He has treated over 1,600 patients with buprenorphine and has worked in licensed Opiate Treatment programs providing all three FDA-approved medications for OUD treatment.

    Matt Tierney has no relevant financial disclosures.


    image

    Deanna Wilson, MD, MPH

    image

    Dr. Deanna Wilson is an Assistant Professor of Medicine and Pediatrics at the University of Pittsburgh School of Medicine. She received her MD from Yale University School of Medicine and trained in internal medicine and pediatrics at the Johns Hopkins University School of Medicine. She also completed additional subspecialty training in both adolescent and addiction medicine at Johns Hopkins.

    Dr. Deanna Wilson has no relevant financial disclosures.


    How to Claim Credits


    To claim continuing education (CE) and/or continuing medical education (CME) credit, follow the steps below.

    STEP 1

    Complete all the content modules in the course located under "Course Content." Each module contains instructional materials, interactive exercises, and knowledge checks.

    STEP 2

    Complete the post-course evaluation. Fill out the survey by clicking the blue "Fill out Survey" button. Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window. Submit the evaluation (the next box should activate, and the evaluation box should turn green with a white check mark).

    STEP 3

    Click the button “Claim Credits” in the box titled "Download Course Certificate." Choose the type of credit (Physician or Non-physician) and click submit. Click the button “View/Print Certificate” to save or print your certificate. If you ever lose your certificate, you can come back to the ASAM e-Learning Center and view it on your transcript (found in the Dashboard).

    Credits and Disclosures


    Date of Release: January 2020 

    Approved Through: December 2021

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians (AAFP)

    The AAFP has reviewed The ASAM Treatment of Opioid Use Disorder Course and deemed it acceptable for up to 8.00 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 12/01/2020 to 12/01/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity

    AMA / AAFP Equivalency

    AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

    American Board of Surgery (ABS)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    Benjamin Bearnot, MD - Does Disclose

    • We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board 

    • Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty and Planning Committee


    Faculty Disclosure Information

    Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures 
    Mount Sinai Beth Israel, New York, NY

    Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures 
    First Judicial District Court, Santa Fe, NM

    Matt Tierney, APRN - No Relevant Financial Disclosures 
    University of California - San Francisco, San Francisco, CA

    Yngvild Olsen, MD, MPH, DFASAM – No Relevant Financial Disclosures 
    Institute for Behavior Resources, Inc., Baltimore, MD


    Planning Committee Disclosure Information

    Melissa Weimer, DO, MCR, FASAM, Chair – Does Disclose

    • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

    Deanna Wilson, MD, MPH, Vice Chair – No Relevant Financial Disclosures
    Pittsburgh, PA

    Alta DeRoo, MD, FASAM – Does Disclose

    • Indivior, Speaker honorarium
    • Alkermes, Speaker honorarium

    Soraya Azari, MD – No Relevant Financial Disclosures
    San Francisco, CA

    Kristin Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
    Atlanta, GA

    Matt Tierney, NP, CNS – No Relevant Financial Disclosures
    San Francisco, CA

    Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
    Santa Fe, NM

    Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
    New York, NY

    • Register
      • Non-Member - $199
      • Regular Member - $149
      • Retired - $149
      • Early Career Physician - $149
      • Resident - Free!
      • Student - Free!
      • Associate - $149
      • ASAM Staff - Free!
      • International Member - $149
      • Emeritus Member - $149
      • Provisional Member - $149
      • Fellow Member - $149
      • Honorary Member - $149
      • CRT Member - $199
    • More Information
  • The Association of Loneliness and Non-prescribed Opioid Use in Patients With Opioid Use Disorder (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the association of loneliness and non-prescribed opioid use in patients with opioid use disorder.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the association of loneliness and non-prescribed opioid use in patients with opioid use disorder. John McDonagh, MD, FASAM, Cory B. Williams, BS, Benjamin J. Oldfield, MD, MHS, Dabely Cruz-Jose, AS, and Douglas P. Olson, MD

    Learning objectives: 

    1. Identify the potential physical and psychological causes of loneliness.

    2. Understand the UCLA Loneliness Scale Version 3.

    3. Determine if there is a relationship between loneliness and non-prescribed opioid use in patients diagnosed with opioid use disorder (OUD).

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity authors have disclosed relevant financial relationship information and it is determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Do sex differences among adults with opioid use disorder reflect sex-specific vulnerabilities? A study of behavioral health comorbidities, pain, and quality of life (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about sex differences among adults with opioid use disorder.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about sex differences among adults with opioid use disorder. Taeho Greg Rhee, PhD, MSW, MacKenzie R. Peltier, PhD, Mehmet Sofuoglu, MD, PhD, and Robert A. Rosenheck, MD

    Learning objectives: 

    1. Examine the prevalence of comorbid burden and quality of life between men and women by opioid use disorder (OUD) status.

    2. Compare risks of comorbid burden and quality of life between men and women by OUD status.

    3. Evaluate comorbid burden and quality of life between adults with OUD and those without OUD and if they are different by sex.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity authors have disclosed relevant financial relationship information and it is determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Greater Attention Paid to the Patient’s Experience Could Improve the Treatment of Individuals With Opioid Use Disorder Hospitalized for Serious Infections (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the improvement of patient experiences with opioid use disorder who have been hospitalized for serious infections.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the improvement of patient experiences with opioid use disorder who have been hospitalized for serious infections. Joji Suzuki, MD

    Learning objectives: 

    1. Recognize the need to improve treatment for patients with opioid use disorder.

    2. Understand the journey mapping process to plan a patient with OUD treatment plan.

    3. Determine treatment methods to treat patients with OUD with infective endocarditis. 

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity authors have disclosed relevant financial relationship information and it is determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Caron Treatment Center's 5th Annual Addiction Research Symposium: A Webinar Series

    Contains 20 Component(s), Includes Credits

    Showcasing the latest evidence-based practices, treatment models and cutting-edge research, this event bridges the gap between practice and research to improve the care of those suffering from substance use disorders.

    image

    5th Annual Addiction Research Symposium: A Webinar Series

    Overview

    Showcasing the latest evidence-based practices, treatment models and cutting-edge research, this event bridges the gap between practice and research to improve the care of those suffering from substance use disorders.  Leading experts in the field of Addiction Medicine from across the country will enlighten the audience about current and future treatment possibilities being explored by researchers today.

    This year’s symposium will be conducted as a webinar series, once weekly for five weeks starting Wednesday, October 21st.  All sessions will be held on Zoom and will be 1.5 – 2 hours in length.

    This event is appropriate for those who work in the field of Addiction Medicine, including psychiatrists, addiction medicine physicians, medical residents and students, medical researchers, nurse practitioners, physician assistants, and medical educators.  Additionally, those who work with the addicted population, such as psychologists, behavioral health therapists, and addiction therapists, will find value in attending (check with your licensing board for eligibility of credits).

    Registration Information:

    • Wednesday, October 21| 10:30 am - 12:00 pm (ET)
    • Wednesday, October 28| 10:30 am - 12:00 pm (ET)
    • Wednesday, November 4| 10:30 am - 12:00 pm (ET)
    • Wednesday, November 11| 10:30 am - 12:00 pm (ET)
    • Tuesday, November 17| 10:30 am - 12:30 pm (ET)

    Cost: $99 per attendee.

    Register for the ASAM Fundamentals of Addiction Medicine AND Caron Treatment Center's 5th Annual Addiction Research Symposium together for a $30 discount!  Please add both the Fundamentals AND the Caron Symposium products to your e-Learning Center shopping cart to receive the discount.

    Please view the Session Details tab for topics, speakers and objectives.
    All sessions will be recorded.  If you are unable to join any of the live sessions, you may watch the recording and complete the evaluation at a later time.

    Questions:

    Please email Katelyn Stine at kstine@caron.org or call 610-743-6525 with any questions.  If you need to cancel your registration, please email education@asam.org.

    Wednesday, October 21, 2020
    10:30 AM – 12:00 PM 

    Presentation #1: “Challenges and Potential for Medical Marijuana and CBD Oil”
    Speaker: Kent Vrana, PhD – Chair, Department of Pharmacology, Penn State College of Medicine

    Learning Objectives:

    1. Compare and contrast medical marijuana programs in Pennsylvania and the rest of the nation.
    2. Describe barriers to, and potential concerns for, medical marijuana research.
    3. Discuss differences and similarities in marijuana versus hemp (THC versus CBD).

     

    Wednesday, October 28, 2020
    10:30 AM – 12:00 PM

    Presentation #2: “A Systematic Review of the Research on Alcoholics Anonymous and Twelve-Step Facilitation Treatments”
    Speaker: John Kelly, PhD, ABPP - Elizabeth R. Spallin Professor of Psychiatry in Addiction Medicine, Harvard Medical School

    Learning Objectives:

    1. Describe the clinical and public health benefits derived from Alcoholics Anonymous.
    2. Understand the differences between Alcoholics Anonymous and 12-Step facilitations.
    3. Name three different styles of 12-Step Facilitation interventions.

     

    Wednesday, November 4, 2020             
    10:30 AM – 12:00 PM

    Presentation #3: “The Brain Dopamine System and Opioid Use Disorder”
    Speaker: Peter Manza, PhD – Research Fellow, National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes of Health (NIH)

    Learning Objectives:

    1. Understand the role of dopamine signaling in addiction generally.
    2. Describe the role of dopamine signaling in opioid use disorder.
    3. Identify how different dopamine receptor subtypes are affected in opioid use disorder.

     

    Wednesday, November 11, 2020           
    10:30 AM – 12:00 PM

    Presentation #4: “Penn State Health's Hub and Spoke Model of Care”
    Speaker: Sarah Kawaski, MD - Director, Addiction Services; Assistant Professor, Psychiatry and Internal Medicine; Pennsylvania Psychiatric Institute and Penn State Health

    Learning Objectives:

    1. Understand the evidence behind a Hub and Spoke Model of Care.
    2. Learn how Penn state employs multiple models to treat opioid use disorders.
    3. How to collaborate within and among institutions to achieve the best outcomes for the community.

     

    Tuesday November 17, 2020
    10:30 AM – 12:30 PM 

    Presentation #5: “Addiction Medicine, Treatment and Research in the Wake of COVID-19: A Panel Discussion”
    Panelists: Eric Strain, MD - Director, Behavioral Pharmacology Research Unit; Director, Johns Hopkins Center for Substance Abuse Treatment and Research; Executive Vice Chair, JHB Department of Psychiatry and Behavioral Sciences

    Joseph Garbely, DO, DFASAM - Executive Vice President/Chief Medical Officer, Caron Treatment Centers; Program Director of the Addiction Medicine Fellowship, Caron Treatment Centers; Chairman of the Physician in Training Committee, American Society of Addiction Medicine (ASAM)

    William Santoro, MD, FASAM, DABAM - President, Pennsylvania Society of Addiction Medicine (PSAM); Chief, Section of Addiction Medicine, Tower Health System, Department of Family & Community Medicine

    Learning Objectives:

    1. List retrospective “lessons learned” in addiction treatment that have surfaced with the onset of the COVID-19 pandemic.
    2. Identify best practices that have emerged in the treatment of patients affected by substance use disorder in both inpatient and outpatient settings amidst the COVID-19 pandemic. 
    3. Describe alterations that will need to occur in the field of Addiction Medicine to successfully treat patients and conduct research while being mindful of safety and mitigation efforts for COVID-19. 

    Kent Vrana

    PhD

    Kent E. Vrana, PhD is the Elliot S. Vesell Professor and Chair of Pharmacology at the Penn State College of Medicine and Milton S. Hershey Medical Center.  He received his BS with honors in Biochemistry from the University of Iowa in 1978, and his PhD in Biochemistry (Pharmacology minor) from Louisiana State University Medical Center in 1983. His post-doctoral fellowship training was in embryology and molecular biology at the Carnegie Institution of Washington in Baltimore, MD (on the Johns Hopkins University campus). Following faculty positions at the West Virginia University Health Sciences Center and the Wake Forest School of Medicine, Dr. Vrana went to Penn State in 2004.

    Dr. Vrana is a member of the editorial boards of several scientific journals and has served as chair and/or member of over 100 scientific review panel meetings for the National Institutes of Health, the Veterans Administration (VA), and the Department of Defense.  He has co-authored over 150 scientific articles, book chapters, and monographs. He is active in medical education and currently serves as co-director of the Clinical Learning and Competency courses (Problem-Based Learning) for the first and second years of the medical curriculum.

    In 2009, Dr.Vrana was named an honorary professor of the new School of Medicine of the Peruvian University of Applied Science in Lima, Peru.  In recognition of his work in education, he received the 2009 Distinguished Educator Award and was inducted into the Society of Distinguished Educators at the Penn State College of Medicine.

    John Kelly

    PhD

    Dr. Kelly is the Elizabeth R. Spallin Associate Professor of Psychiatry in Addiction Medicine at Harvard Medical School-the first endowed professor in addiction medicine at Harvard. He is also the founder and Director of the Recovery Research Institute at the Massachusetts General Hospital (MGH), the Program Director of the Addiction Recovery Management Service (ARMS) and the Associate Director of the Center for Addiction Medicine at MGH. Dr. Kelly is a former President of the American Psychological Association (APA) Society of Addiction Psychology, and is also a Fellow of the APA and a diplomate of the American Board of Professional Psychology. He has served as a consultant to U.S. federal agencies and non-Federal institutions, and foreign governments. 

    His clinical and research work has focused on addiction treatment and the recovery process, mechanisms of behavior change, and in reducing stigma and discrimination among individuals suffering from addiction

    Peter Manza

    PhD

    Dr. Peter Manza is a postdoctoral fellow in the lab of Dr. Nora Volkow at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). He earned his PhD in integrative neuroscience from Stony Brook University, where he studied how dopaminergic medications influence cognition in Parkinson’s disease. Pete has focused his postdoctoral work on how negative emotionality erodes self-control and contributes to compulsive drug-taking. He uses fMRI, PET, and genetic markers to understand these processes. In his spare time, Pete enjoys playing sports, hiking, and playing guitar.

    Sarah Sharfstein Kawaski

    MD

    Sarah Sharfstein Kawasaki, MD, Assistant Professor of Psychiatry and Director of Addiction Services at PPI.  

    Dr. Kawasaki received her MD at the University of Maryland School of Medicine and completed her internal medicine residency at Johns Hopkins Bayview Medical Center, followed by a Postdoctoral Fellowship at the Center for Behavioral Addiction Medicine, Department of Family Medicine at the University of California, Los Angeles.  Most recently she served as Director of Internal Medicine at Healthcare for the Homeless in Baltimore, MD, where she treated the mentally ill and substance using homeless population in Baltimore.  She is an advocate for smoking cessation and suboxone treatment, for which she is a certified provider.  She has interests in investigating health outcomes in model of treatment, where interdisciplinary teams, including psychiatry, outpatient addiction treatment and case management, work in tandem.

    Eric Strain

    MD

    Dr. Eric Strain is a professor in the Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, and is also the director of the Johns Hopkins Center for Substance Abuse Treatment and Research and the executive vice chair for Psychiatry at Johns Hopkins Bayview Medical Center. He maintains an active research program in substance abuse related issues, provides clinical care to patients, teaches medical students and residents, and provides administrative supervision in the maintenance of current substance abuse programs and the development of new substance abuse initiatives at Johns Hopkins. In addition to his responsibilities at Johns Hopkins, Dr. Strain is the editor-in-chief for the journal Drug and Alcohol Dependence, and is on the editorial board for several other journals. He edited, with Maxine Stitzer, the books Methadone Treatment for Opioid Dependence and The Treatment of Opioid Dependence, and with Pedro Ruiz edited the fifth edition of Lowinson and Ruiz’s Substance Abuse: A Comprehensive Textbook. He was the lead in developing the first buprenorphine curriculum, which was subsequently used as the primary resource to train physicians in the use of this medication for the treatment of opioid dependence.

    Dr. Strain was chair of the Food and Drug Administration’s Drug Abuse Advisory Committee, the National Institutes of Health ARM study section, and the American Psychiatric Association’s Council on Addiction Psychiatry. He has served on the boards of The College on Problems of Drug Dependence (for which he is a past-president), the American Academy of Addiction Psychiatry, and Baltimore Substance Abuse Systems. He also has served on various committees for the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, and the federal Center for Substance Abuse Treatment, and is a frequent reviewer for scientific journals in the area of substance abuse. Dr. Strain is the recipient of several competitive grant awards from the National Institute of Health, and has published extensively on substance abuse-related matters. His research areas have included topics such as the optimal mechanisms for treating patients with substance abuse disorders, including opioid and cocaine dependence, the relationship between substance abuse and other psychiatric disorders, the abuse liability of novel medications, the clinical pharmacology of opioid analgesics, and the development of new pharmacotherapies for substance abuse treatment (including opioids and alcohol). His studies have included medications such as buprenorphine, methadone and LAAM, pharmacotherapies for alcohol dependence, and non-pharmacologic treatments for substance abuse disorders.

    Joseph M. Garbely

    DO, DFASAM

    As executive vice president of medical services and chief medical officer at Caron Treatment Centers, Dr. Garbely oversees the following programs and departments: Healthcare Professionals Program, Chronic Pain Program, Neurocognitive Services Department, Psychology, Research, detoxification and, medical management.

    During his tenure at Caron, Dr. Garbely spearheaded a high-level initiative to educate and train physicians in addiction medicine through the establishment of the Resident Training Program at Caron Pennsylvania. Dr. Garbely established an Accreditation Council for Graduate Medical Education (ACGME) accredited Addiction Medicine Fellowship Program at Caron Pennsylvania and Reading Hospital. As the Addiction Medicine Fellowship director, Dr. Garbely is a member of the American College of Academic Addiction Medicine. He is also a clinical associate professor at Penn State College of Medicine, an adjunct associate professor at Stony Brook School of Medicine, and a member of the medical staff at Reading Hospital.

    Dr. Garbely is the chairman of the Physician in Training Committee of the American Society of Addiction Medicine (ASAM), an ex-officio member of the ASAM Board, and a distinguished Fellow of ASAM. Dr. Garbely received his board certifications through the American Board of Preventative Medicine, Addiction Medicine Subspecialty; the American Board of Internal Medicine; the American Board of Psychiatry and Neurology; and the American Board of Addiction Medicine.

    Prior to his current position, Dr. Garbely served as the vice president of medical services and medical director of Caron Pennsylvania. With 20 years of addiction medicine experience, Dr. Garbely has an extensive background in treating substance use disorders, including substance use disorders in healthcare professionals, executives, and pilots. He has worked to develop treatment programs for psychiatric patients involving a 12-Step philosophy. Dr. Garbely has won teaching awards on the local and national level, including the American Psychiatric Association’s Helen Ruske, MD Award for Excellence in Medical Student Teaching.

    William Santoro

    MD, FASAM, DABAM

    William Santoro, MD is Board Certified in both Family Medicine and Addiction Medicine with nearly 40 years of experience.  He has worked with attorneys for the defense and prosecution as an expert witness in the field of Addiction Medicine.  He is a sought-after speaker for multiple topics in Addiction Medicine, including the treatment of narcotic addiction and nicotine dependence.  Currently, he serves as the Chief of the Section of Substance Use Disorder, Medical Director and Addictionist at The Reading Hospital and Medical Director at New Directions Treatment Services.  Dr. Santoro also was founder and senior partner Laureldale Family Medical Center for 31 years, and Medical Director at Albright College 26 years.  Dr. Santoro graduated from the Central del Caribe School of Medicine in 1981. 

    ACCME Accredited with Commendation

    CME/CE Credits

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this online webinar for a maximum of 8 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ACCME Accreditation Statement

    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The American Society of Addiction Medicine and The Caron Foundation. The American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty:

    Kent Vrana, PhD
    PA Options for Wellness, Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received), Clinical Condition Medical Marijuana
    Penn State University College of Medicine

    William Santoro, MD
    Indivior, Speaker/Honoraria (includes speakers bureau, symposia, and expert witness), Clinical Condition Substance Use Disorder
    Tower Health Addiction Medicine, Reading PA

    Peter Manza, MD – No Relevant Financial Disclosures
    National Institutes of Health, Bethesda, MD

    Eric Strain, MD
    Elsevier, Payment for editing, Clinical Condition: Substance Use Disorder, Analgesic Solutions, Consultant/Advisory Board, Clinical Condition: Substance Use Disorder, Indivior, Consultant/Advisory Board, Clinical Condition: Substance Use Disorder
    Johns Hopkins University SOM, Baltimore, MD

    Sarah Kawasaki, MD – No Relevant Financial Disclosures
    Penn State Health, Hershey, PA

    Joseph Garbely, DO, DFASAM – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    John Kelley, PhD, ABPP – No Relevant Financial Disclosures
    Harvard Medical School, Massachusetts General Hospital, Boston, MA

    Planning Committee:

    Dean Drosnes – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Tammy Granger – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Erin Deneke, PhD – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Olapeju Simoyan – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Kristin Campbell-Salamone
    Caron Treatment Centers, Employment
    Caron Treatment Centers, Wernersville, PA

    David Rotenberg, MA, MBA, LPC – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Jenna Fry – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Maureen Sander, BAAS – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Julie Flannery – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

    Katelyn Stine – No Relevant Financial Disclosures
    Caron Treatment Centers, Wernersville, PA

     

    ASAM CME Committee Reviewer:

    Cara A. Poland, MD, MEd, DFASAM – No Relevant Financial Disclosures


    Caron Treatment Centers

    With 60 years in the field, Caron Treatment Centers operates lifesaving addiction and behavioral healthcare treatment. Caron is headquartered in Wernersville, Pennsylvania, with Ocean Drive and Caron Renaissance located in Palm Beach County, Florida. Caron has recovery centers in New England, Philadelphia and Washington, D.C., which offer community and recovery support. Caron’s Recovery Centers in Atlanta and New York City also offer pre- and post-treatment services. 

    Caron has the most extensive continuum of care including teens, young adults, mid-life adults, older adults, chronic pain, executives, healthcare and legal professionals and families. Caron’s treatment is customized to meet the needs of individuals and families – with highly trained teams prepared to address co-occurring disorders. Caron offers an innovative approach to ongoing recovery care support for its patients and their families with online peer groups and other resources during the first year of transition following discharge. 

    • Register
      • Non-Member - $99
      • Regular Member - $99
      • Retired - $99
      • Early Career Physician - $99
      • Resident - $99
      • Student - $99
      • Associate - $99
      • ASAM Staff - Free!
      • International Member - $99
      • Emeritus Member - $99
      • Provisional Member - $99
      • Fellow Member - $99
      • Honorary Member - $99
      • CRT Member - $99
    • More Information
  • The ASAM Alcohol Withdrawal Management Guideline Webinar Series

    Contains 5 Product(s)

    This 5-part webinar series discusses the ASAM Alcohol Withdrawal Management Guideline. Areas of focus include (1) the fundamentals of the guideline, (2) identification, diagnosis, and initial assessment, (3) monitoring, levels of care, and inpatient/ambulatory treatment, (4) pharmacotherapy, as well as (5) complicated withdrawal and special populations.

    image

    The ASAM Alcohol Withdrawal Management Guideline Webinar Series


    Alcohol is responsible for a multitude of health conditions, including Alcohol Withdrawal Syndrome (AWS). While frequently presented in specialty addiction treatment settings, patients experiencing or at risk for developing AWS also receive care in hospitals, emergency departments, and primary care settings. The current management of patients with AWS is inconsistent across care settings and evidence-based care is often not provided. The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management was developed to address current practice concerns and provide clear guidance that will lead to more consistent treatment practices in the field. The series is primarily intended for clinicians who provide alcohol withdrawal management in specialty and non-specialty addiction treatment settings. 

    All webinars in the series will be free for ASAM members to join live and watch the recorded on-demand session. For non-ASAM members, it will be free to join live and watch on-demand webinars for 90-days after the live webinar date. Following the 90 days, non-ASAM members can purchase the on-demand webinars for $39 each or at a discounted price for the entire 5-webinar package. The first webinar focused on the Fundamentals will continue to be free for everyone. 

    Webinar Series Topics & Dates

    1. Fundamentals: Wednesday, July 29, 2020; 1:00 pm ET
    2. Identification, Diagnosis & Initial Assessment: Monday, August 24, 2020; 1:00 pm ET 
    3. Monitoring, Levels of Care & Inpatient/Ambulatory Treatment: Tuesday, September 15, 2020; 1:00 pm ET
    4. Pharmacotherapy: Tuesday, October 20, 2020; 12:00 pm ET
    5. Complicated Withdrawal and Special Populations: Tuesday, November 17, 2020; 12:00 pm ET
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 5 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


    • Register
      • Non-Member - Free!
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM Alcohol Withdrawal Management Webinar Series – Complicated Withdrawal & Special Populations

    Contains 4 Component(s), Includes Credits

    The fifth and final of its series, this webinar will provide an overview of the The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management's recommendations around both complicated withdrawal and special populations.

    image


    The ASAM Alcohol Withdrawal Management Webinar Series – Complicated Withdrawal & Special Populations


    The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

    Aspects of management may need to be adjusted for patients with or at risk for complicated AWS, such as the development of alcohol withdrawal seizure or alcohol withdrawal delirium, alcohol-induced psychotic disorder, or resistant alcohol withdrawal. Special considerations should also be given to specific populations including patients with medical conditions, patients who take opioids, and patients who are pregnant. This webinar will provide an overview of the treatment recommendations around both complicated withdrawal and special populations.

    Session Information

    Date:  Live webinar on Tuesday, November 17, 2020, this session is now available on-demand as a recorded webinar.  

    Speaker(s): Darius Rastegar, MD, FASAM

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Summarize the guideline’s treatment recommendations around complicated withdrawal and discuss how they should be used in practice. 
    • 2. Identify the different types of complicated withdrawal and how management should be adjusted for each.
    • 3. Describe the different special populations and how management should be adjusted for each.

    Darius Rastegar, MD, FASAM

    Associate Professor of Medicine, Johns Hopkins University School of Medicine

    Dr. Rastegar is a general internist and addiction specialist at Johns Hopkins Bayview Medical Center.  He provides outpatient primary care with a focus on caring for patients with substance use disorders, inpatient consultantions and is the medical director for an inpatient unit for treatment of substance withdrawal. He is also the program director for the Johns Hopkins Addiction Medicine fellowship and the co-author of the ASAM Handbook of Addiction Medicine.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


    • Register
      • Non-Member - Free!
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Pain Management and Opioids: Balancing Risks and Benefits - University of Washington School of Nursing - Friday, January 15, 2021

    Contains 4 Component(s), Includes Credits

    Earn 4 AMA PRA Category 1™ Credits while learning about the latest science, clinical guidelines, and policies around pain and opioids and getting the tools you need to provide evidence-based pain treatment.

    image

    Host: University of Washington School of Nursing

    Date: Friday January 15, 2021 | 1:00 pm – 5:00 pm PT

    Virtual Live Course

    Cost: Free

    The misuse of opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 1999 to 2016 more than 630,000 people died from drug overdoses.
    • 115 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculumaddresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018. 

    This product is worth a total of 4 AMA PRA Category 1™ Credits.

    Marianne Fingerhood, DNP, ANP-BC

    Adult Nurse Practitioner

    Marianne Fingerhood, DNP, ANP-BC has been a nurse for 34 years. She has been a nurse practitioner in adult primary care for 20 years and a clinical preceptor and nursing instructor for the past 18 years. In all settings, she has brought a passion for education, whether it be with patients, students or colleagues. As a nurse practitioner with Johns Hopkins Community Physicians she is the champion for an initiative to expand access to treatment for substance use disorder in the primary care setting.  Her role in the Johns Hopkins School of Nursing is focused on providing education on chronic pain, safe opioid prescribing, recognition and treatment of SUD. Her area of interest is continued support and education for Nurse Practitioners as they transition into their roles as primary care providers.

    Credits and Disclosures


    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 4 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 4 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 4 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    Catherine Friedman, MD, FAPA, DFASAM – No Relevant Financial Disclosures 

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty 


    Marianne Fingerhood, CRNP – No Relevant Financial Disclosures 
    Owings Mills, MD


    • Register
      • Non-Member - Free!
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM Alcohol Withdrawal Management Webinar Series - Pharmacotherapy

    Contains 4 Component(s), Includes Credits

    The fourth of its series, this webinar will provide an overview of the The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management's recommendations around the appropriate use of pharmacotherapy for patients with AWS.

    image


    The ASAM Alcohol Withdrawal Management Webinar Series – Pharmacotherapy


    The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

    Appropriate pharmacotherapy for alcohol withdrawal is a balance of alleviating symptoms and normalizing signs of AWS while preventing the adverse effects associated with the medications being administered. This webinar will provide an overview of the recommendations around the appropriate use of pharmacotherapy for patients with AWS. 

    Session Information

    Date: Live webinar on Tuesday, October 20, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Michael F. Weaver, MD, FASAM

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Summarize the guideline’s treatment recommendations around pharmacotherapy and discuss how they should be used in practice.  
    • 2. Recognize all medications that can be used to treat patients with AWS and explain the circumstances in which one form of medication is more effective than another.
    • 3. Understand the limitations and risks associated with the various medications used to treat patients with AWS.

    Michael Weaver

    MD, DFASAM

    Michael Weaver, MD, DFASAM is a Professor in the Department of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addictions (CNRA) at the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He received his M.D. degree from Northeast Ohio Medical University, and completed Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University (VCU) Health System, and he is Board-certified in Internal Medicine through the American Board of Internal Medicine and certified in Addiction Medicine through the American Board of Preventive Medicine. Dr. Weaver is the Sub-Board Chair for Addiction Medicine on the American Board of Preventive Medicine, and also serves as the Chair of the Examination Committee for certification in Addiction Medicine. He has been a member of ASAM for over 20 years and currently serves as a member of the Publications Council and the Annual Conference Program Planning Committee. He is currently involved in patient care, medical education, and research. Dr. Weaver sees patients in the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston. He has extensive experience teaching about addiction to medical students, residents, and community professionals at all levels. He has been involved in multiple research projects, and currently is collaborating with other researchers in the CNRA on studies involving cocaine, methamphetamine, marijuana, and electronic cigarettes. Dr. Weaver has multiple publications in the field of addiction medicine, including the book "Addiction Treatment" published by Carlat Publishing in 2017.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM Fundamentals of Addiction Medicine - Virtual Live Workshop - October 6, 7, 13 and 14, 2020 - In collaboration with Caron Treatment Centers

    Contains 13 Component(s), Includes Credits

    Earn continuing education credits while attending this innovative live virtual workshop designed to support providers new to the field of addiction medicine, in settings such as primary care, emergency care, and behavioral health settings, who see patients at risk for or with addiction. Learn how to screen, diagnose, treat, and/or refer patients with addiction.

    image

    in collaboration with

    image

    Registration Information

    This virtual workshop will be held online over the course of four days. Participants should plan to attend all four days at the designated times:

    • Tuesday, October 6 | 1:00 pm - 3:00 pm (ET)
    • Wednesday, October 7 | 1:00 pm - 4:00 pm (ET)
    • Tuesday, October 13 | 1:00 pm - 3:30 pm (ET)
    • Wednesday, October 14 | 1:00 pm - 4:00 pm (ET)

    Cost: $129 per attendee.  

    Register for the ASAM Fundamentals of Addiction Medicine AND Caron Treatment Center's 5th Annual Addiction Research Symposium together for a $30 discount!  Please add both the Fundamentals AND the Caron Symposium products to your e-Learning Center shopping cart to receive the discount.

    Overview

    The ASAM Fundamentals of Addiction Medicine is an innovative, case-based workshop designed for providers new to the field of addiction medicine in settings such as primary care, emergency care, and behavioral health, who see patients at risk for or with substance use disorders (SUDs). Participants will learn more about addiction medicine and how to screen, diagnose, treat, and/or refer patients with addiction*. Addiction is a disease that continues to devastate our communities, but there are treatments available to help patients. Participants of this workshop will learn more about addiction medicine and how to screen, diagnose, treat, and/or refer patients with addiction – many of whom are already being seen for commonly occurring medical and psychiatric comorbidities. 

    This live virtual workshop is designed to be energetic and interactive. Sessions throughout the series will include lecture, demonstration of skills and skill building. Participants should plan to attend all four days of sessions at the designated dates and times above. Sessions will be recorded for participants to view after the series concludes. 

    *Note: This program is the first activity in The ASAM Fundamentals of Addiction Medicine 40-Hour Program, an innovative educational program designed to translate the science of addiction medicine into transformative, positive outcomes for patients by empowering primary care and other providers to diagnose and treat patients at risk for or with addiction. Participants of this live workshop will receive a discount off the registration price for the full 40-Hour Program, featuring over 80 hours of CME content to choose from and a community of mentors and colleagues for additional support with complex patients! To learn more visit: https://www.asam.org/education/live-online-cme/fundamentals-program

    Learning Objectives

    Upon completion of this educational activity, participants should be able to:
    1. Identify one's own feelings and attitudes that promote or prevent therapeutic responses to patients with substance use disorders.
    2. Demonstrate a knowledge of the diseased brain processes when treating patients with addictive behaviors.
    3. Use validated patient screening tools to detect substance use and interpret a spectrum of results.
    4. Use motivational interviewing to enhance patient's readiness to change risky behaviors.
    5. Offer the interventions that are appropriate to specific substances and severity of usage pattern.
      1. Respond to hazardous drinking with brief counseling strategies, appropriate to the patient's readiness to change.
      2. For patients suspected of having a SUD, conduct a biopsychosocial assessment to provide a diagnosis and match the patient to an appropriate level of care.
    6. Prescribe pharmacotherapy appropriately for alcohol, tobacco, and opioid use disorders.
    7. Offer patients and families information and referral to behavioral interventions including support groups and mutual aid groups that assist in the recovery process.

    Registration Cancellation Policy

    Please email education@asam.org for all cancellation requests or issues/concerns if a day is no longer feasible with your schedule. We will do our best to work with participants who are unable to attend for urgent responsibilities to ensure all CME hours can be claimed.

    Questions?

    If you have any questions or comments, please feel free to reach out to Samantha Cribari-Starr, Director of Professional Development at ASAM.  

    Session 1: An Introduction to Addictive Disorders and the Clinical Manifestations of the Neurobiology of Addiction

    DAY 1 - October 6, 2020; 1:00 pm - 3:00 pm ET

    The first part of this session you will (1) be immediately engaged through a powerful, visual medium; (2) identify and reflect upon their individual affective response to the disease of substance use disorder and their patients who show evidence of this disease, and (3) identify and discuss the many factors associated with SUD, e.g., enabling behaviors of others in the life of the person who is using substances, the effect of pejorative language when caring for people who use substances, etc. 

    The second part of the session will introduce the neurobiology of SUD, highlighting that this is a chronic illness and noting that the point of first entry into the healthcare system is through the primary care physician.

    ActivityTiming
    ASAM Welcome and Instructions 20 Min
    Session 1: Overview and An Introduction to Addictive Disorders45 Min
    Session 2: The Clinical Manifestations of the Neurobiology of Addiction45 Min
    Day 1 Wrap-Up and Housekeeping10 Min
    Total Time Day 12 Hour

    Session 2: Identifying Unhealthy Substance Use: Assessment and For Every ill, There May Be a Pill: Treating Substance Use Disorders with Medication and Counseling

    DAY 2 - October 7, 2020; 1:00 pm - 4:00pm ET

    The first part of this session will provide an overview of the assessment and treatment plan for patients with severe addictive disorders. Ben’s case will be continued with a biopsychosocial assessment and corresponding recommended treatment plan. The ASAM Patient Placement Criteria will be introduced, and participants will practice using these criteria. The second part of this session will engage participants in dialogue about medications and behavioral treatments including mutual aid groups that may be used to treat three types of SUDs: alcohol, tobacco, opioids.

    ActivityTiming
    ASAM Welcome and Instructions20 Min
    Session 3: Identifying Unhealthy Substance Use: Assessment 1 Hour
    Session 4: For Every ill, There May Be a Pill: Treating Substance Use Disorders
    With Medication and Counseling
    1 Hour, 30 Min
    Day 2 Wrap-Up and Housekeeping10 Min
    Total Time Day 23 Hour

    Session 3: Should I Open Pandora’s Box? Screening, Brief Intervention, and Referral to Treatment (SBIRT)

    DAY 3 - October 13, 2020; 1:00 pm - 3:30 pm ET

    The purpose of this session is to provide further training and skills practice in screening and brief intervention with consequent indicated referral to treatment for persons with alcohol use or substance use disorder.

    ActivityTiming
    ASAM Welcome and Instructions20 Min
    Session 5: Should I Open Pandora’s Box?: Screening, Brief Intervention,
    and Referral to Treatment (SBIRT)
    2 Hour
    Day 3 Wrap-Up and Housekeeping10 Min
    Total Time Day 32 Hour, 30 Min

    Session 4: When Your Patient says Yes, But! A “Taste” of Motivational Interviewing

    DAY 4 - October 14; 1:00 pm to 4:00 pm ET

    The purpose of this session is to introduce the approach to motivational interviewing and provide an opportunity for participants to practice using the MI approach in interacting with patients.

    ActivityTiming
    ASAM Welcome and Instructions20 Min
    Session 6: When Your Patient says Yes, But!: A “Taste” of Motivational
    Interviewing
    2 Hour, 25 Min
    Day 4 Wrap-Up15 Min
    Total Time Day 43 Hour

    Joseph M. Garbely

    DO, DFASAM

    As executive vice president of medical services and chief medical officer at Caron Treatment Centers, Dr. Garbely oversees the following programs and departments: Healthcare Professionals Program, Chronic Pain Program, Neurocognitive Services Department, Psychology, Research, detoxification and, medical management.

    During his tenure at Caron, Dr. Garbely spearheaded a high-level initiative to educate and train physicians in addiction medicine through the establishment of the Resident Training Program at Caron Pennsylvania. Dr. Garbely established an Accreditation Council for Graduate Medical Education (ACGME) accredited Addiction Medicine Fellowship Program at Caron Pennsylvania and Reading Hospital. As the Addiction Medicine Fellowship director, Dr. Garbely is a member of the American College of Academic Addiction Medicine. He is also a clinical associate professor at Penn State College of Medicine, an adjunct associate professor at Stony Brook School of Medicine, and a member of the medical staff at Reading Hospital.

    Dr. Garbely is the chairman of the Physician in Training Committee of the American Society of Addiction Medicine (ASAM), an ex-officio member of the ASAM Board, and a distinguished Fellow of ASAM. Dr. Garbely received his board certifications through the American Board of Preventative Medicine, Addiction Medicine Subspecialty; the American Board of Internal Medicine; the American Board of Psychiatry and Neurology; and the American Board of Addiction Medicine.

    Prior to his current position, Dr. Garbely served as the vice president of medical services and medical director of Caron Pennsylvania. With 20 years of addiction medicine experience, Dr. Garbely has an extensive background in treating substance use disorders, including substance use disorders in healthcare professionals, executives, and pilots. He has worked to develop treatment programs for psychiatric patients involving a 12-Step philosophy. Dr. Garbely has won teaching awards on the local and national level, including the American Psychiatric Association’s Helen Ruske, MD Award for Excellence in Medical Student Teaching.

    Dean Drosnes

    MD

    Dr. Dean Drosnes is the Medical Director of the Pennsylvania campus of Caron Treatment Centers. He holds board certification in Addiction Medicine through the American Board of Preventive Medicine as well as Otolaryngology/Head and Neck Surgery and. He is a Fellow of the American Society of Addiction Medicine and serves on the ASAM Physicians-In-Training Committee. He is a member of the American College of Academic Addiction Medicine, the Pennsylvania Society of Addiction Medicine, and the Alpha Omega Alpha Honor Medical Society. He holds an appointment as Clinical Assistant Professor of Psychiatry, Penn State University College of Medicine.

    Dr. Drosnes completed his Fellowship in Addiction Medicine at the University of Maryland. He received his undergraduate degree at the University of Pittsburgh and his medical education from Temple University. He completed his post-graduate training in Otolaryngology/Head and Neck surgery at Thomas Jefferson University.

    Dr. Drosnes’ clinical practice focuses on the treatment of co-existing substance use and chronic pain disorders. He emphasizes the integrated use of pain treatment modalities that are compatible with lifelong recovery from addiction.

    Olapeju Simoyan

    MD, MPH, BDS, FAAFP

    Dr. Simoyan is a clinical associate professor in the Department of Psychiatry and Behavioral Health at Penn State College of Medicine and serves as core faculty for the Caron/Reading Hospital addiction medicine fellowship.

    Before coming to Caron in February 2020, she was the associate medical director at Geisinger Marworth Treatment Center in Waverly, Pennsylvania, and the program director of Geisinger’s addiction medicine fellowship. She was a member of the founding faculty of the Geisinger Commonwealth School of Medicine (formerly The Commonwealth Medical College) where she held the rank of associate professor of family medicine and epidemiology.

    Dr. Simoyan earned her medical degree from Penn State University College of Medicine, after which she completed an internship in psychiatry/family medicine at the University of Pittsburgh Medical Center/Western Psychiatric Institute. She completed her family medicine residency at the Penn State/Good Samaritan Hospital Family and Community Medicine Residency program.

    Prior to her medical training, Dr. Simoyan received a dental degree from the University of Ibadan in Nigeria and a Master of Public Health degree from the Johns Hopkins University Bloomberg School of Public Health.

    She is board certified in family medicine, addiction medicine, and dental public health and has contributed to international public health education as a Fulbright specialist in Nigeria and an Erasmus Mundus scholar in France and the United Kingdom. She has also volunteered on medical mission projects in Nigeria and Haiti.

    Dr. Simoyan is a member of the Addiction Medicine Sub-board of the American Board of Preventive Medicine and serves on the REACH Program Advisory Board, a program that aims to mentor and cultivate culturally responsive fellows and trainees, who are equipped to address healthcare inequities in addiction.

    Dr. Simoyan’s scholarships and awards include the Emerging Leader award from the Family Medicine Education Consortium (2010) and the American Association of Medical Colleges’ Herbert Nickens Faculty Fellowship (2012). She was recognized by the Northeastern Pennsylvania Business Journal as one of the “Top 25 Women in Business in 2015,” and she was a second-prize winner in the State Department’s Citizen Diplomacy Challenge in the same year.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this internet-based live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians

    This Live activity, The ASAM Fundamentals of Addiction Medicine: A Live Workshop, from 04/02/2020 - 04/02/2021, has been reviewed and is acceptable for up to 8.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Association of Nurse Practitioners
    This activity is approved for 8.0 contact hour(s) of continuing education (which includes 2.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20024155. This activity was planned in accordance with AANP Accreditation Standards and Policies.

    American Academy of Physician Assistants
    This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 8.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Fundamentals of Addiction Medicine Workshop Planning Committee

    Name

    Disclosure

    Miriam S. Komaromy, MD, FACP, FASAM (Chair)

    No Financial Relationships or Conflicts of Interest

    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM, (Immediate Past Chair)

    Johnson and johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment

    Zwaantje H. Hamming, FNP-C, CARN-AP

    No Financial Relationships or Conflicts of Interest

    Marcia Jackson, PhD

    No Financial Relationships or Conflicts of Interest

    Jill Mattingly, DHSc, MMSc, PA-C

    No Financial Relationships or Conflicts of Interest

    Lipi Rpy, MD, MPH DABAM

    Poynter Institute: Teaching/Training, Honorarium; Florida Hospital: Teaching/Training, Honorarium; Rescue Agency: Consulting, Fee

    Kenneth A. Saffier, MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Mario F. San Bartolomé, MD, MBA, MRO, QME, FASAM

    No Financial Relationships or Conflicts of Interest

    J. Paul Seale, MD, FASAM

    No Financial Relationships or Conflicts of Interest

    Alexander Walley, MD, MSc, FASAM

    No Financial Relationships or Conflicts of Interest

     

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Cara Poland, MD, MEd, FACP, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    Caron Treatment Centers

    With 60 years in the field, Caron Treatment Centers operates lifesaving addiction and behavioral healthcare treatment. Caron is headquartered in Wernersville, Pennsylvania, with Ocean Drive and Caron Renaissance located in Palm Beach County, Florida. Caron has recovery centers in New England, Philadelphia and Washington, D.C., which offer community and recovery support. Caron’s Recovery Centers in Atlanta and New York City also offer pre- and post-treatment services. 

    Caron has the most extensive continuum of care including teens, young adults, mid-life adults, older adults, chronic pain, executives, healthcare and legal professionals and families. Caron’s treatment is customized to meet the needs of individuals and families – with highly trained teams prepared to address co-occurring disorders. Caron offers an innovative approach to ongoing recovery care support for its patients and their families with online peer groups and other resources during the first year of transition following discharge. 

    • Register
      • Honorary Member - $129
      • CRT Member - $129
      • Non-Member - $129
      • Regular Member - $129
      • Retired - $129
      • Early Career Physician - $129
      • Resident - $129
      • Student - $129
      • Associate - $129
      • ASAM Staff - Free!
      • International Member - $129
      • Emeritus Member - $129
      • Provisional Member - $129
      • Fellow Member - $129
      • Honorary Member - $129
      • CRT Member - $129
    • More Information
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Clayton, MO - Wednesday, December 9, 2020

    Product not yet rated Contains 6 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Centene Corporation

    Date: Wednesday, December 9, 2020 | 1:00 pm - 5:30 pm CT |2:00 pm - 6:30 pm ET

    Live Virtual Course

    Online Portion Due: Tuesday, December 8, 2020

    Overview 

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting Started 

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions.If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    Module 1 

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    Edwin Salsitz

    MD, DFASAM

    Edwin Salsitz, MD, DFASAM has been an attending physician at Mt. Sinai Beth Israel, Division of Chemical Dependency, in New York City since 1983, and is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics. 

    Dr. Salsitz is Curriculum Director for The ASAM Treatment of Opioid Use Disorder Course and is a mentor in the PCSS-MAT mentoring program. He has co-chaired The ASAM Review Course, The ASAM Pain & Addiction: Common Threads Course, The ASAM State of the Art Course in Addiction Medicine and is a reviewer for the Journal of Addiction Medicine. He is the chair of The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives Course. 

    He is a member of the ASAM Medical Education Council and the ASAM CME Committee and is Chair of the New York Society of Addiction Medicine CME and Education Committees. Dr. Salsitz is a member of the medical advisory panel for the New York State Office of Alcohol and Substance Abuse Services. He is the recipient of the 2014 ASAM Annual Award and the 2018 ASAM Educator of the Year Award.

    Credits and Disclosures


    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

    American Board of Surgery (ABS)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    Benjamin Bearnot, MD – Does Disclose

    • We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board
    • Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty and Planning Committee


    Faculty Disclosure Information

    Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures 
    Mount Sinai Beth Israel, New York, NY


    Planning Committee Disclosure Information

    Melissa Weimer, DO, MCR, FASAM – Does Disclose

    • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

    Deanna Wilson, MD, MPH– No Relevant Financial Disclosures
    Pittsburgh, PA

    Alta DeRoo, MD, FASAM – Does Disclose

    • Indivior, Speaker honorarium
    • Alkermes, Speaker honorarium

    Soraya Azari, MD – No Relevant Financial Disclosures
    San Francisco, CA

    Kristen Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
    Atlanta, GA

    Matt Tierney, NP, CNS – No Relevant Financial Disclosures
    San Francisco, CA

    Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
    Santa Fe, NM

    Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
    New York, NY

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may upload copies of their training certificates on the Waiver Notification Form. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    • Register
      • Non-Member - Free!
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Rockville, MD - Friday, December 18, 2020

    Contains 7 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Treatment of Opioid Use Disorder Course: Ob-Gyn Focus

    Date: Friday, December 18, 2020 | 1:00 pm - 5:30 pm ET

    Live Virtual Course

    Online Portion Due: Thursday, December 17, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Credits and Disclosures


    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    California Consortium of Addiction Programs and Professionals (CCAPP)

    This educational program is approved by CCAPP: #OS-20-330-1222

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification


    American Board of Preventive Medicine (ABPM)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    American Board of Anesthesiology (ABA)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    American Board of Pediatrics (ABP)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    American Board of Internal Medicine (ABIM)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

    American Board of Surgery (ABS)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    American Board of Addiction Medicine (ABAM)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    CME Reviewer and Disclosure Information


    ASAM CME Committee Reviewer

    Benjamin Bearnot, MD – Does Disclose

    • We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board
    • Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    Faculty and Planning Committee


    Faculty Disclosure Information

    Kirk Moberg, MD, PhD, DFASAM - No Relevant Financial Disclosures

    Alta DeRoo, MD, FASAM – Does Disclose

    • Indivior, Speaker honorarium
    • Alkermes, Speaker honorarium

    Planning Committee Disclosure Information

    Melissa Weimer, DO, MCR, FASAM – Does Disclose

    • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

    Deanna Wilson, MD, MPH– No Relevant Financial Disclosures
    Pittsburgh, PA

    Alta DeRoo, MD, FASAM – Does Disclose

    • Indivior, Speaker honorarium
    • Alkermes, Speaker honorarium

    Soraya Azari, MD – No Relevant Financial Disclosures
    San Francisco, CA

    Kristen Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
    Atlanta, GA

    Matt Tierney, NP, CNS – No Relevant Financial Disclosures
    San Francisco, CA

    Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
    Santa Fe, NM

    Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
    New York, NY

    How to Apply for a Waiver

    Physicians

    • Fill out the Waiver Notification Form on SAMHSA’s website. You can upload a copy of your training certificate directly in the waiver application form.

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may upload copies of their training certificates directly to the waiver notification form. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    • Register
      • Non-Member - $25
      • Regular Member - $25
      • Retired - $25
      • Early Career Physician - $25
      • Resident - $25
      • Student - $25
      • Associate - $25
      • ASAM Staff - Free!
      • International Member - $25
      • Emeritus Member - $25
      • Provisional Member - $25
      • Fellow Member - $25
      • Honorary Member - $25
      • CRT Member - $25
    • More Information
  • Calls for Access to Safe Injecting Supplies as a Critical Public Health Measure During the COVID-19 Pandemic (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about access to safe injecting supplies as a critical public health measure during the COVID-19 pandemic.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about access to safe injecting supplies as a critical public health measure during the COVID-19 pandemic. Koharu Loulou Chayama, MSc, Cara Ng, MA, and Ryan McNeil, PhD

    Learning objectives: 

    1. Recognize the negative impact COVID-19 has on people who inject drugs (PWID).

    2. Identify barriers to accessing safe injecting sites for PWID during the COVID-19 pandemic.

    3. Describe harm reduction strategies that can be taken to improve PWID lives during the COVID-19 pandemic.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity authors have disclosed relevant financial relationship information and it is determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – Adolescents & Young Adults


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    Adolescents and young adults present for treatment with a broad spectrum of opioid use disorder severity with a range of co-occurring medical and psychiatric illnesses. The treatment of youth with opioid use disorder presents many unique medical, legal, and ethical dilemmas that may complicate treatment. Given these unique issues, adolescents and young adults often benefit from services designed specifically for them. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating youth with OUD from the ASAM National Practice Guideline.

    Session Information 

    Date: Live webinar on Thursday, September 24, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Marc Fishman, MD

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for adolescents and young adults with OUD and discuss how they should be used in practice. 
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for adolescents and young adults.
    3. Recognize the unique needs and treatment recommendations for adolescents and young adults

    Marc Fishman

    MD

    Marc Fishman MD is a specialist in  addiction psychiatry and addiction medicine.  He is a member of the faculty of the Department of Psychiatry at the Johns Hopkins University School of Medicine. He leads Maryland Treatment Centers, which offers programs for residential and outpatient treatment of drug-involved and dual-diagnosis adolescents and adults. He has written and lectured widely on a variety of topics including youth treatment, placement and treatment matching strategies, co-occurring disorders, and medication treatment for addiction. His research focus has been in treatment of opioid use disorders in youth. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine, and a current memeber of its Board.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM National Practice Guideline 2020 Focused Update Webinar Series

    Contains 5 Product(s)

    This 5-part webinar series discusses the ASAM National Practice Guideline 2020 Focused Update. Topics include the fundamentals of the guideline update, and topics specific to pregnant women, opioid use disorder and pain, individuals in the Criminal Justice System, and adolescents and young adults.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar Series


    Opioid use disorder is a chronic, relapsing disease, which has significant economic, personal, and public health consequences. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use was developed to assist in the evaluation and treatment of opioid use disorder. Topics covered included: opioid withdrawal management, psychosocial treatment, special populations, and opioid overdose. The ASAM Guideline was the first guideline to address all medications available in the U.S. for the treatment of opioid addiction and overdose, in a single document. Since its publication in 2015, new medications and science in the field emerged, compelling ASAM to conduct a focused update.

    This 5-part webinar series discusses the ASAM National Practice Guideline 2020 Focused Update. Topics include the fundamentals of the guideline update, and topics specific to pregnant women, opioid use disorder and pain, individuals in the Criminal Justice System, and adolescents and young adults. This webinar series is primarily intended for clinicians involved in evaluating patients and providing authorization for pharmacological treatments at any level. 

    All webinars in the series will be free for ASAM members to join live and watch the recorded on-demand session. For non-ASAM members, it will be free to join live and watch on-demand webinars for 30-days after the live webinar date. Following the 30 days, non-ASAM members can purchase the on-demand webinars for $39 each or at a discounted price for the entire 5-webinar package. The first webinar focused on the Fundamentals will continue to be free for everyone. 

    Webinar Series Topics & Dates

    1. Fundamentals: Tuesday, May 26, 2020; 12:00 pm ET
    2. Pregnant Women: Tuesday, June 30, 2020; 2:00 pm ET
    3. OUD and Pain: Tuesday, July 21, 2020; 1:00 pm ET
    4. Individuals in the Criminal Justice System: Thursday, September 10, 2020; 12:00 pm ET
    5. Adolescents and Young Adults: Tuesday, September 24, 2020; 1:00 pm ET

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 5 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


    • Register
      • Non-Member - $175
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Oklahoma City, OK - Tuesday, November 10, 2020

    Product not yet rated Contains 7 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Oklahoma Perinatal Quality Improvement Collaborative (OPQIC)

    Date: Tuesday, November 10, 2020 | 8:00 am - 12:30 pm CT

    Live Virtual Course

    Online Portion Due: Monday, November 9, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    • Register
      • Non-Member - $25
      • Regular Member - $25
      • Retired - $25
      • Early Career Physician - $25
      • Resident - $25
      • Student - $25
      • Associate - $25
      • ASAM Staff - Free!
      • International Member - $25
      • Emeritus Member - $25
      • Provisional Member - $25
      • Fellow Member - $25
      • Honorary Member - $25
      • CRT Member - $25
    • More Information
  • Treatment of Opioid Use Disorder: Waiver Qualifying - Portland, OR - Friday, November 6, 2020

    Contains 7 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

    Host: Oregon Perinatal Quality Collaborative & Comagine Health

    Date: Friday, November 6, 2020 | 8:00 am - 12:30 pm PT 

    Live Virtual Course

    Online Portion Due: Thursday, November 6, 2020

    This course is offered in partnership with the American College of Obstetricians and Gynecologists (ACOG). The curriculum for this course has been specifically designed for women's health providers.

    Overview

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live in person or via live webinar learning. The live in person or via live webinar portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live in person or via live webinar portion. You must complete both portions to receive credit for the course. 

    Getting Started

    To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.  If you have any questions, please contact education@ASAM.org.

    Learning Objectives

    1. Identify the importance of screening for substance use disorders
    2. Describe the mechanism of opioid withdrawal
    3. Discuss options to treat opioid withdrawal
    4. Explain the safety and efficacy of buprenorphine to treat opioid use disorder
    5. Explain the safety of medications in antepartum, postpartum, and breastfeeding period
    6. Describe how to start a patient (induction) on buprenorphine in an office-based setting
    7. Discuss successful non-pharmacological ways to treat Neonatal Abstinence Syndrome

    Overall Objective

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder.

    Target Audience

    1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    NameNature of Relevant Financial Relationship
    Dan Alford, MD, MPH, DFASAM, ChairNone
    Edwin Salsitz, MD, DFASAM, Curriculum DirectorNone
    Alta DeRoo, MD, FASAM, FACOGNone
    Soraya Azari, MDNone
    Jill Mattingly, DHSc, MMSc, PA-CNone
    Debra Newman, PA-C, MPAS, MPHCommercial Interest: AbbVie
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Commercial Interest: Gilead
    What was received: Honoraria
    Role: Expert faculty for CME activities
    Mary McMasters, MD, DFASAMNone
    Yngvild K. Olsen, MD, MPH, DFASAMNone
    Shawn Ryan, MD, MBA, FASAMCommercial Interest: Crosswave 
    What was received: Stock 
    Role: Advisor
    Commercial Interest: Dynamicare
    What was received: Stock
    Role: Advisor
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, DFASAMNone

    ASAM CME Committee

    NameNature of Relevant Financial Relationship
    Catherine Friedman, MD, FAPA, DFASAM, ChairNone
    Catharina Armstrong, MD, MPHNone
    Subhadeep Barman, MD, FASAM, FAPANone
    Benjamin Bearnot, MD, MPH, FASAMCommercial Interest: Johnson and Johnson
    What was received: Common stock
    Role: None
    Commercial Interest: Baxter International
    What was received: Common stock
    Role: None
    Commercial Interest: Takeda Pharmaceuticals
    What was received: Common stock
    Role: none
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMCommercial Interest: Alkermes
    What was received: Travel expenses
    Role: Speaker
    Zwaantje H. Hamming, FNP-C, CARN-APNone
    Herbert L. Malinoff, MD, FACP, DFASAM None
    Noel Ilogu, MD, MRCP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
     ASAM Staff and Consultants
    Arlene C. Deverman, MA, CAE, CFRENone
    Sandy MetcalfeNone
    Kate M. BrundageNone

    ASAM Medical Education Council

    NameNature of Relevant Financial Relationship
    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, ChairCommercial Interest: Johnson & Johnson; Novartis; Pfizer Inc.
    What was received: Received free/discounted materials for research studies through an open tender process
    Role: Research Studies
    Commercial Interest: Pfizer Inc. Global Research Awards for Nicotine Dependence (GRAND).
    What was received: Grant funds
    Role: Principal investigator on research study
    Commercial Interest: Johnson & Johnson E-NRT Advisory Board
    What was received: Consulting Fees
    Role: Consulting on Johnson & Johnson E-NRT Advisory Board
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Brian Hurley, MD, MBA, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
     ASAM Staff and ConsultantsNone
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. PiotrowskiNone
    Molly S. MazukNone
    Alexandra (Alli) KrouseNone
    Jennifer L. ButchartCommercial Interest: Merck
    What was received: Spouse received stocks
    Role: Stockholder


    How to Apply for a Waiver

    Physicians

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Other Approved Prescribers

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to csatbupinfo@dsgonline.com. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

    NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

    • Register
      • Non-Member - $25
      • Regular Member - $25
      • Retired - $25
      • Early Career Physician - $25
      • Resident - $25
      • Student - $25
      • Associate - $25
      • ASAM Staff - Free!
      • International Member - $25
      • Emeritus Member - $25
      • Provisional Member - $25
      • Fellow Member - $25
      • Honorary Member - $25
      • CRT Member - $25
    • More Information
  • The ASAM Alcohol Withdrawal Management Webinar Series – Monitoring, Levels of Care, & Inpatient/Ambulatory Treatment

    Contains 4 Component(s), Includes Credits

    The third of its series, this webinar will provide an overview of the The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management's recommendations for monitoring patients with AWS in varying settings and levels of care.

    image


    The ASAM Alcohol Withdrawal Management Webinar Series – Monitoring, Levels of Care, & Inpatient/Ambulatory Treatment 


    The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

    Level of care determinations should be based on an evaluation of the expected risks and benefits of treatment within each setting and monitoring a patient with AWS should include multiple indicators of withdrawal progress and patient health. Given that alcohol withdrawal management services are provided in both inpatient and ambulatory settings, this webinar will provide an overview of the recommendations for monitoring patients with AWS in these varying settings and levels of care. 

    Session Information

    Date: Live webinar on Tuesday, September 15, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): George Kolodner, MD, DLFAPA, FASAM

    Learning Objectives

    By completing this session, you will be able to:

    • 1. Understand how to make an appropriate level of care determination for patients seeking alcohol withdrawal management services. 
    • 2. Identify the level of care determination tools available to help determine the appropriate level of care for patients with AWS.
    • 3. Summarize the guideline’s treatment recommendations around inpatient and ambulatory settings and recognize the difference in the services provided in each setting. 

    George Kolodner

    MD, DLFAPA, FASAM

    George Kolodner, MD, FASAM is the Medical Director of the Kolmac Clinic, a Clinical Professor of Psychiatry at both the Georgetown And University Schools of Medicine, and the current president of MDSAM, the Maryland State Chapter of ASAM. His specialty interests are the treatment of addictions in an outpatient setting and the treatment of co-occurring disorders.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring live course for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Ed Salsitz, MD, DFASAM - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Lewis S. Nelson, MD, FASAM (Chair) – No Relevant Financial Disclosures

    Kurt Kleinschmidt, MD, FASAM – No Relevant Financial Disclosures

    Gerald E. Marti, MD, PhD – No Relevant Financial Disclosures

    Darius Rastegar, MD, FASAM – No Relevant Financial Disclosures

    Dazhe Cao, MD – No Relevant Financial Disclosures

    George Kolodner, MD, DLFAPA, FASAM – Does Disclose: Kolmac Outpatient Recovery Centers, Self, Employment, Ownership Interest (includes stock, stock options, patent or other intellectual property) Clinical Condition: Substance Use Disorder

    Michael F. Weaver, MD, DFASAM – No Relevant Financial Disclosures


    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System

    Contains 4 Component(s), Includes Credits

    This session will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.

    image

    The ASAM National Practice Guideline 2020 Focused Update Webinar – Individuals in the Criminal Justice System


    This webinar follows the ASAM National Practice Guideline 2020 Focused Update Fundamentals webinar, which outlines the new and updated recommendations in the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder

    A substantial proportion of persons in prisons, jails, drug courts, probation, parole, and who are criminally involved have opioid use disorder and related problems. The high concentration of at-risk individuals and conditions of incarceration can increase the risk of adverse consequences associated with drug use, including violence, medical and psychiatric co-morbidity, drug-related deaths, self-harm and suicide. Furthermore, treatment of OUD in CJ settings has all too often been sub-standard. For example, when individuals are released from incarceration without OUD treatment, they are at extreme risk of relapse overdose and death. This webinar will provide an overview of the new and updated recommendations and in-depth information on treating individuals in the criminal justice system from the ASAM National Practice Guideline.

    Session Information 

    Date: Live webinar on Thursday, September 10, 2020, this session is now available on-demand as a recorded webinar

    Speaker(s): Sandra Springer, MD

    Learning Objectives 

    By completing this webinar, you will be able to:

    1. Summarize the guideline’s treatment recommendations for individuals in the criminal justice system with OUD and discuss how they should be used in practice.
    2. Identify the fundamental components of an OUD patient assessment and diagnosis for individuals in the criminal justice system.
    3. Recognize the unique needs and treatment recommendations for individuals in the criminal justice system

    Sandra Springer

    MD

    Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, Section of Infectious Diseases at the Yale School of Medicine. Dr. Springer is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. In addition, she is the Director of the Infectious Disease Clinic at the Newington site of the VA Connecticut Healthcare System where she oversees the care of Veterans living with HIV (VLH). She graduated from Harvard University, then later received her Medical Degree from University of Massachusetts Medical School. She did her Internal Medicine Residency and Infectious Disease Fellowship at Yale School of Medicine. Dr. Springer has significant clinical and research experience with persons living with HIV disease (PLH) and those with comorbid substance use disorders (SUD). Her research has focused on evaluation of integration of SUD and HIV treatments. In particular, she has focused on medication treatment for opioid use disorder (OUD) (MOUD) and medication treatment for alcohol use disorders (AUD) to improve substance use relapse outcomes and HIV treatment outcomes, especially among those released from prison and jail. Dr. Springer has been continuously NIH funded for over 15 years. She has a K02 Independent Scientist Award from NIDA evaluating medication treatment for OUD (MOUD) interventions among PLH. Dr. Springer has been a buprenorphine provider since 2005, and performed the first evaluation of the use of buprenorphine to prevent relapse to opioid use and improve HIV viral suppression among PLH released from prison. She created and later validated a rapid opioid dependency screen (RODS) that quickly identifies if someone has a moderate to severe opioid use disorder (OUD) to quickly initiate MOUD. She has studied extended-release naltrexone (XR-NTX) as a PI on a 5 year NIAAA-funded R01 which used a RCT design to evaluate its effect on improving HIV viral suppression for PLH released from prison; and she was a PI on a NIDA-funded R01 within the Seek Test Treat and Retain (STTR) Criminal Justice System (CJS) consortium to evaluate the use of XR-NTX to improve HIV VS among PLH with OUD released from prison/jail.  Dr. Springer was a working group member of the NIDA STTR consortium that harmonized outcomes across 23 NIDA-funded STTR studies involving PLH and those who are at risk for HIV. Additionally, she was co-I on 2 NIDA R01s (1) using Buprenorphine to improve HIV treatment outcomes among CJS-involved PLH with OUD in Washington, D.C.; and (2) implementing XR-NTX among PLH with OUD in Ukraine. She is currently co-PI on a 5-year R01 from NIDA evaluating the impact of HIV infection on immunologic, transcriptomic, and metabolomic signatures among PLH compared to those without HIV infection who are beginning MAT for OUD. She is a co-PI with Drs. Ho and Kluger at Yale for a NIDA funded R33/R61 that is specifically evaluating the impact of all forms of MAT on HIV persistence; and she is a co-I on a HEALing NIDA funded grant to combat Opioid addiction in NY State. She is also the contact PI of a new U01 from NCATS that will integrate ID and injectable buprenorphine in hospitalized patients. She also is a co-PI on a new Justice involved HEALing grant at the NYU site with Dr. Josh Lee from NIDA evaluating OUD medication treatment for criminal justice involved persons with OUD and co-PI with Dr. Ismene Petrakis for a VA COOP grant among 900 Veterans with OUD comparing injectable and sublingual buprenorphine. She is a member of IDSA and HIVMA’s expert panel to integrate ID and OUD, a NASEM committee member evaluating the integration of ID and OUD treatment and prevention in community settings nationally, and a member of the ASAM committee that provided updated recommendations for use of MOUD in 2020. 

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this live internet-based activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC)

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. 

    ASAM CME Committee Reviewer

    Subhadeep Barman, MD, FASAM, FAPA - No Financial Disclosures

    Faculty & Planning Committee Disclosures

    Kyle M. Kampman, MD – Does Disclose: World Meds (Clinical Condition: Opioid Use Disorder): Consultant/Advisory Board 

    Marc Fishman, MD – Does Disclose: Alkermes (Clinical Condition: OUD): Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

    Tricia Wright, MD, MS, DFASAM – Does Disclose McKesson (Clinical Condition: Opioid use in pregnancy): Consultant/Advisory Board

    Sandra Springer, MD – Does Disclose: Alkermes Inc (Clinical Condition: Substance Use Disorder) Consultant/Advisory/Board, reviewed research grants for young investigators Clinical Care Options INc (Clinical Condition: Infectious disease) Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)

    George Woody, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory/Board, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) Indivior (Clinical Condition: opioid use disorders) Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) World Meds (Clinical Condition: Opioid Use Disorders) Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support)

    Daniel Langleben, MD – Does Disclose: Alkermes Inc (Clinical Condition: Opioid Use Disorder) Consultant/Advisory Board 

    Stephen A. Wyatt, DO, FAOAAM, FASAM (Chair) – No Financial Disclosure

    Timothy Wiegand, MD, FACMT, FAACT, DFASAM – No financial Disclosures


    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information
  • Policies to Improve Substance Use Disorder Treatment With Telehealth During the COVID-19 Pandemic and Beyond (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about policies to improve substance use disorder treatment with telehealth during the COVID-19 pandemic and beyond.

    Earn 1 AMA PRA Category 1 Credit(s)TM while learning about policies to improve substance use disorder treatment with telehealth during the COVID-19 pandemic and beyond. Coleman Drake, PhD, Jiani Yu, PhD, Nicole Lurie, MD, Kevin Kraemer, MD, MSc, Daniel Polsky, PhD, and Krisda H. Chaiyachati, MD, MPH, MSHP

    Learning objectives: 

    1. Recognize the need to expand SUD programs during the COVID-19 pandemic.

    2. Describe why permanent tele-SUD treatment options would contribute to positive health outcomes. 

    3. Identify the four steps to transition to permanent tele-SUD treatment.

    ACCME Accredited with Commendation

    CME/CE Credits

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NAADAC, the Association for Addiction Professionals

    This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

    California Association for Drug/Alcohol Educators (CAADE)

    This educational program is approved by CAADE: #CP40 999 1222

    California Association of DUI Treatment Centers (CADTP)

    This educational program is approved by CADTP: #205

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    Maintenance of Certification (MOC)

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credit towards ABPM MOC Part II requirements.

    ABA Maintenance of Certification (MOC)

    This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

    ABP Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 1 MOC point in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

     ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    ABAM Transitional Maintenance of Certification (Tmoc)

    Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

    American Board of Psychiatry and Neurology (ABPN)

    Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

    Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

    In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity authors have disclosed relevant financial relationship information and it is determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    • Register
      • Non-Member - $39
      • Regular Member - Free!
      • Retired - Free!
      • Early Career Physician - Free!
      • Resident - Free!
      • Student - Free!
      • Associate - Free!
      • ASAM Staff - Free!
      • International Member - Free!
      • Emeritus Member - Free!
      • Provisional Member - Free!
      • Fellow Member - Free!
      • Honorary Member - Free!
      • CRT Member - Free!
    • More Information